Related Experiment Video
Updated: Jun 2, 2026
14:45
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model
Kang-Woo Lee1, Walter Chen, Eunsung Junn
1Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA.
Summary
Enhancing carboxyl methylation of phosphoprotein phosphatase 2A (PP2A) reduced alpha-synuclein (α-Syn) phosphorylation and aggregation in Parkinson's disease models. This therapeutic strategy improved neuronal function and motor performance.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alpha-synuclein (α-Syn) aggregation and hyperphosphorylation at serine 129 are pathological hallmarks of Parkinson's disease (PD).
- Serine 129 phosphorylation is implicated in α-Syn aggregation and neurotoxicity, presenting a potential therapeutic target.
Purpose of the Study:
- To investigate the role of phosphoprotein phosphatase 2A (PP2A) in α-Syn dephosphorylation.
- To evaluate the therapeutic potential of enhancing PP2A activity for treating α-synucleinopathies.
Main Methods:
- Demonstrated PP2A dephosphorylates α-Syn at serine 129.
- Investigated the effect of PP2A carboxyl methylation on its activity.
- Utilized α-Syn-transgenic mice fed a diet supplemented with eicosanoyl-5-hydroxytryptamide to enhance PP2A methylation.
Main Results:
- Enhanced PP2A methylation significantly reduced α-Syn phosphorylation at serine 129 and brain aggregation.
- Observed improved neuronal activity, increased dendritic arborizations, and reduced neuroinflammation (astroglial and microglial activation).
- Demonstrated significant improvements in motor performance in treated mice.
Conclusions:
- Serine 129 phosphorylation of α-Syn is pathogenetically significant in neurodegenerative disorders.
- Promoting PP2A activity via enhanced methylation is a viable disease-modifying therapeutic strategy for Parkinson's disease and related α-synucleinopathies.
